- Home
- IPSC vs ECOR Comparison
IPSC vs ECOR Comparison
Compare IPSC & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- ECOR
- Stock Information
- Founded
- IPSC 2019
- ECOR 2005
- Country
- IPSC United States
- ECOR United States
- Employees
- IPSC N/A
- ECOR N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IPSC Health Care
- ECOR Health Care
- Exchange
- IPSC Nasdaq
- ECOR Nasdaq
- Market Cap
- IPSC 49.6M
- ECOR 39.7M
- IPO Year
- IPSC 2021
- ECOR 2018
- Fundamental
- Price
- IPSC $0.60
- ECOR $7.08
- Analyst Decision
- IPSC Strong Buy
- ECOR Strong Buy
- Analyst Count
- IPSC 5
- ECOR 2
- Target Price
- IPSC $3.33
- ECOR $25.50
- AVG Volume (30 Days)
- IPSC 1.0M
- ECOR 120.2K
- Earning Date
- IPSC 08-07-2025
- ECOR 08-06-2025
- Dividend Yield
- IPSC N/A
- ECOR N/A
- EPS Growth
- IPSC N/A
- ECOR N/A
- EPS
- IPSC N/A
- ECOR N/A
- Revenue
- IPSC $114,898,000.00
- ECOR $26,458,000.00
- Revenue This Year
- IPSC $1,064.82
- ECOR $23.21
- Revenue Next Year
- IPSC N/A
- ECOR $44.10
- P/E Ratio
- IPSC N/A
- ECOR N/A
- Revenue Growth
- IPSC 8286.72
- ECOR 41.54
- 52 Week Low
- IPSC $0.34
- ECOR $4.47
- 52 Week High
- IPSC $3.29
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- IPSC 55.47
- ECOR 70.90
- Support Level
- IPSC $0.52
- ECOR $5.13
- Resistance Level
- IPSC $0.57
- ECOR $8.64
- Average True Range (ATR)
- IPSC 0.04
- ECOR 0.64
- MACD
- IPSC 0.00
- ECOR 0.30
- Stochastic Oscillator
- IPSC 66.10
- ECOR 70.38
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.